While most of Wall Street focuses on large and large-cap stocks because they offer a degree of safety and liquidity, many investors are limited in the number of stocks they can buy. Many of the biggest public companies, especially the tech giants, trade in the hundreds, up to over $1,000 per share or more. At these high prices, it’s hard to get decent leverage on the number of shares.
Many investors, especially more aggressive traders, look to low priced stocks as a way to not only make money, but also get a higher number of shares. This can really help the decision-making process, especially when you’re on to a winner, because you can always sell half and keep half.
We scoured our 24/7 research database on Wall St. for well-known companies that could very well offer patient investors huge returns for the remainder of 2022 and beyond. Low-priced stock skeptics should remember that at one point, Amazon and Apple were trading in single digits. A stock we’ve featured over the years, Zynga, was recently purchased by Take-Two Interactive. Cogent Biosciences, which we presented in March, doubled.
Although all five stocks are rated Buy, it is important to remember that no single analyst report should be used as the sole basis for any buy or sell decision.
blue apron
A major shareholder has just made another large investment in the stock. Blue Apron Holdings Inc. (NASDAQ: APRN) operates a direct-to-consumer platform that features original recipes with fresh, seasonal ingredients.
The Company also operates Blue Apron Market, an e-commerce marketplace that provides kitchen tools, utensils, pantry items and other products. The company offers Blue Apron Wine, a direct-to-consumer wine delivery service that sells wines that can accompany their meals. It serves young couples, families, singles and empty nests. The Company offers its services through order selections on websites or mobile applications primarily in the United States.
RJB Partners, a subsidiary of Joseph N. Sanberg, has agreed to increase its investment in the company from $20 million to $50 million in a private placement. Blue Apron is seeking to use proceeds from the private placement to invest in its long-term growth plan, with $25 million for strategic purposes, including exploring share buybacks. Upon closing, Sanberg Chief Investment Officer Alex Chalunkal will join Blue Apron’s board of directors.
Lake Street has a target price of $9 on Blue Apron stock. The consensus target is $9.33. The stock last traded Friday at $3.81, up nearly 4%.
ALSO READ: Why You Should Sell The Rally And Buy These 7 Dividend Blue Chips From Goldman Sachs’ Conviction List
Bluebird Organic
This stock is about to break through the 200-day moving average. Bluebird Bio Inc. (NASDAQ: BLUE) is a biotechnology company that researches, develops and commercializes transformative gene therapies for serious genetic diseases.
